newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

  • AEON Biopharma appointed Paul Lee, M.D., Ph.D. as acting Chief Regulatory Officer to lead the regulatory strategy for its biosimilar ABP-450.
  • Dr. Lee will continue advising AEON through Clintrex Research LLC, an affiliate of BlueRidge Life Sciences, on regulatory & clinical development.
  • Dr. Lee previously served as Deputy Director of the FDA's Office of Neuroscience from May 2024 to June 2025.
  • In his prior FDA roles, he oversaw reviews for neurological & psychiatric conditions including migraine, epilepsy, stroke, multiple sclerosis, & neurodegenerative diseases.
  • Dr. Lee recently co-authored a publication regarding the FDA approval of Tyruko, the first biosimilar to natalizumab.
  • ABP-450 is a biosimilar to BOTOX designed for full-label U.S. therapeutic market entry via the 351(k) pathway.
  • The product is the same botulinum toxin complex marketed as Jeuveau by Evolus for cosmetic indications.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, EU, UK, & other international territories.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.